CN216696345U - Platelet function testing device and kit - Google Patents

Abstract

The utility model provides a platelet function testing device and a kit, and relates to the technical field of blood function testing. The device comprises a bottom plate, wherein a sample chamber, a sample passage, a stirring chamber and a blood flow passage are prefabricated on the bottom plate. The inner wall of the stir chamber has a platelet-inducer coating thereon and the inner wall of the blood flow path has an extracellular matrix protein coating thereon. The platelet function testing device has no complex sampling system and motion control system, and eliminates the potential cross contamination risk and testing uncertainty of sampling. And the testing device can completely simulate the environment in the blood vessel, and improves the accuracy, consistency and reliability of the test. In addition, the platelet function testing device is simple in design, greatly reduces the purchase and maintenance cost of the testing system, and has good maintainability.

Description

Platelet function testing device and kit

Technical Field

The utility model relates to the technical field of blood function test, in particular to a platelet function test device and a platelet function test kit.

Background

At present, the biochemical test, the hemagglutination test and the platelet function test equipment commonly use a separate sample cup, a reagent cup and a reaction cup. The sample and the reagent are respectively stored in a sample cup and a reagent cup, and when the biochemical test is carried out, the sample and the reagent are respectively sucked by a sampling device, moved into a reaction cup and reacted in the reaction cup.

In hemagglutination and platelet testing, coagulation and optical turbidimetry (LTA) are commonly used. The core of the method is to detect products generated in the reaction process of a blood sample and a reagent by an optical method, record the blood coagulation process by detecting the change of a scattered light signal, and obtain a coagulation curve. The optical turbidimetry is characterized in that blood is centrifuged to obtain platelet-rich plasma (PRP), a series of platelet inducers (arachidonic acid, adenosine diphosphate and epinephrine) with different concentrations are adopted to stimulate the platelet-rich plasma, the platelet aggregation and precipitation result in reduced plasma turbidity, and the light transmittance is increased by light source irradiation, so that the aggregation degree between activated platelets is measured.

The detection operation flow of this test is shown in fig. 1: taking whole blood containing 3.2% sodium citrate anticoagulant as a sample, obtaining plasma (PRP) rich in platelets (stored in a reaction cup 1) and plasma (PPP) without platelets (stored in the reaction cup 2) through centrifugation, measuring the PPP light intensity value in the reaction cup 2 through an optical system to be used as a target value of 100% platelet aggregation rate, then measuring the PRP in the reaction cup 1, adding a platelet inducer to generate reaction, recording the reaction process, and comparing the PPP light intensity value when the reaction is terminated to calculate the platelet aggregation rate. Throughout the procedure, plasma and reagents are stored in separate sample cups. The reaction was completed in a reaction cuvette. And the sample to be tested and the reagent are moved into the reaction cup through the sampling mechanism for testing. The reagent can be applied manually or automatically. In the fully automatic blood coagulation instrument system, the test process is completed by matching a sample sampling system, a reagent sampling system and a motion control system together. The system is very complex in design and is relatively cumbersome to maintain and debug.

Although the existing full-automatic hemagglutination test technology and reagent are widely applied, the most significant defects are that the equipment system is complex, the operation is complicated, the cost is high, and the test process can not completely simulate the blood vessel environment. The solidification time is tested by using a solidification method or an optical turbidimetry, the testing time is long, cross contamination is easy to cause, and the consistency of the testing result is to be improved.

In view of this, the utility model is particularly proposed.

SUMMERY OF THE UTILITY MODEL

The utility model aims to provide a platelet function testing device and a kit to solve the technical problems.

The utility model is realized by the following steps:

the utility model provides a platelet function testing device, which comprises a bottom plate, wherein a sample chamber, a sample passage, a stirring chamber and a blood flow passage are prefabricated on the bottom plate, the sample chamber is communicated with the stirring chamber through the sample passage, and the stirring chamber is communicated with the blood flow passage; the inner walls of the sample chamber and the stir chamber have a platelet-inducer coating, platelet-inducer beads or microparticles thereon, and the inner walls of the blood flow path have an extracellular matrix protein coating.

The inventor provides an integrated device for testing platelet function based on the problems of the prior art. The functional test device is capable of simulating hemodynamic conditions in vivo, including platelet induction, adhesion to extracellular matrix (ECM) substrates, aggregation-induced flow cessation, and the like, and can thereby provide diagnostic results that are consistent with clinical results.

Specifically, by providing a platelet-inducer coating on the inner wall of the stirring chamber, the platelet-inducer coating on the stirring chamber is rapidly dissolved into the blood from the sample chamber by the stirring action of the stirring chamber, thereby inducing platelets, simulating in vivo platelet activation or inhibition. Based on the stirring power provided by the stirring chamber, the blood flows into the blood flow path distributed with the extracellular matrix protein coating, thereby simulating the whole process of extracellular matrix (ECM) substrate adhesion and platelet aggregation to cause hemostasis blockage. Causing the microfluid to gradually stop flowing, thus judging the function of the platelet by the Migration Distance (MD) of the blood flow path through which the blood flows.

Compared with the prior art, the platelet function testing device provided by the utility model has no complex sampling system and motion control system, and eliminates the potential cross contamination risk and testing uncertainty of sampling. And the testing device can completely simulate the environment in the blood vessel, and improves the accuracy, consistency and reliability of the test. In addition, the platelet function testing device is simple in design, greatly reduces the purchase and maintenance cost of the testing system, and has good maintainability. The platelet function testing device provided by the utility model can be used for testing the platelet function without waiting for coagulation and directly loading the sample, and has the advantage of short testing time.

The stirring chamber can be provided with stirring blades or stirring rods, and can also be a liquid conveyor belt, a conveying plate or a rotary waterwheel, and devices which can meet the transmission and delivery of blood can be arranged in the stirring chamber. The stirring action is to provide the power for blood flow. In an alternative embodiment, for automation, a motor may be provided at the respective stirring blade or the stirring drive end to satisfy the power transmission.

In one embodiment, a magnetic stirring rod is provided, and a motor arranged below the stirring rod drives impellers with opposite magnetic poles to rotate, so that stirring is realized, and power is provided for blood flow.

The coating on the inner wall of the blood flow conduit may be provided at different positions as required, for example, the coating may be provided at certain intervals, or a continuous coating may be selected, and the surface coating may be provided to simulate the environment of a damaged blood vessel.

The coating was prepared by the following method. The coating is applied to the tubing by dropping it onto the micro tubing with a controlled dosing device and allowing it to dry naturally. The microsphere coating structure is realized by a special extrusion process.

In a preferred embodiment of the present invention, the platelet-inducer is selected from the group consisting of a platelet aggregation promoter and/or a platelet aggregation inhibitor;

the platelet aggregation promoter is at least one selected from the group consisting of:

ADP, epinephrine, and thromboxane a 2;

the platelet aggregation inhibitor is selected from antiplatelet drugs; preferably, the antiplatelet agent is selected from the group consisting of a thromboxane A2 inhibitor, an ADP-P2Y12 receptor antagonist, a thrombin receptor antagonist, a 5-hydroxytryptamine (5-HT) receptor antagonist, a platelet Glycoprotein (GP) IIb/IIIa receptor inhibitor, or a phosphodiesterase inhibitor.

Thrombin A2 (TXA)₂) The inhibitor is selected from at least one of the following substances: aspirin, Arachidonic Acid (AA) and alprostadil (PGE 1). In other embodiments, the platelet aggregation inhibitor may also be selected from other thromboxane synthase inhibitors such as dipyridamole, picolitamide, terbogrel, dartbiotron, seratrodast, SQ-29548 and ramatroban; and thromboxane receptor antagonists such as terbogrel and terlutripan.

Adenosine Diphosphate (ADP) -P2Y12 receptor antagonist mechanism of action is to antagonize the P2Y12 protein, thereby preventing ADP from binding to the P2Y12 receptor. This results in a reduction in platelet aggregation, thereby preventing thrombosis. The P2Y12 receptor is a surface-binding protein found on platelets. They belong to the G protein-coupled purinergic receptors (GPCRs) and are chemical receptors for ADP. Examples of ADP-P2Y12 receptor inhibitors include, but are not limited to, thienopyridines such as clopidogrel, prasugrel and ticlopidine or salts thereof; and nucleotide/nucleoside analogs/receptor antagonists such as cangrelor, enoogrel, ticagrelor, suramin sodium, and 2-MeSAMP.

Thrombin receptor antagonists include, but are not limited to, Vorapaxar (SCH-530348), Atopaxar (E5555).

5-hydroxytryptamine (5-HT) receptor antagonists include, but are not limited to, sarpogrelate, citalopram.

Glycoprotein IIb/IIIa, also known as integrin α IIb β 3, is an integrin complex found on platelets. It is a receptor for fibrinogen and von Willebrand (von Willebrand) factor and contributes to platelet activation. Glycoprotein IIb/IIIa inhibitors can be used to prevent blood clots to reduce the risk of heart attack or stroke. Examples of glycoproteins IIb/IIIa include, but are not limited to, abciximab, eptifibatide (also known as integrin), orbofiban, lotrafiban, roxifiban, sirafiban and tirofiban (also known as icarit) or salts thereof. Preferred glycoprotein IIb/IIIa inhibitors are eptifibatide and tirofiban or salts thereof.

Phosphodiesterase inhibitors include, but are not limited to: dipyridamole, cilostazol, triflusal, milrinone, anagrelide, theophylline or zizipodale (Dipyridamole). Inhibitors of phosphodiesterase can prolong or enhance the action of cAMP or cGMP mediated physiological processes by inhibiting phosphodiesterase degradation, thereby inhibiting platelet function.

In a preferred embodiment of the present invention, the extracellular matrix protein is at least one selected from the group consisting of: fibrinogen, collagen, von willebrand factor (vWF), Tissue Factor (TFs), prothrombin, tissue thromboplastin, accelerometer, serum thrombin, antihemophilic factor, plasma thromboplastin component, plasma thromboplastin precursor, contact factor, or fibrin-stabilizing factor.

In a preferred embodiment of the present invention, the number of the stirring chambers is the same as the number of the blood flow paths. For example, 2, 3, 4 or 5 stir chambers may be provided to satisfy platelet multiplexing detection, with 2, 3, 4 or 5 blood flow paths being provided accordingly.

When the number of the stirring chambers is two, the sample passage is led out from one sample chamber and divided into two branch sample passages, the two branch sample passages are respectively communicated with the two stirring chambers, and the two blood flow passages are respectively communicated with the two stirring chambers.

The two stirring chambers are symmetrically distributed along the central axis of the sample chamber, and the two blood flow passages are symmetrically distributed along the central axis of the sample chamber. The central axis of the sample chamber may be the central axis of symmetry of the sample chamber.

In one embodiment, the branch sample channel and the blood flow channel may be each a channel formed by a groove provided in the bottom plate. In other embodiments, the tubular structure may be fixed to the base plate as a sample path or a blood flow path, for example, by gluing (dispensing), clipping, or bolting the outer wall of the tube to the base plate. The tube may be made of plastic, glass, or the like.

In a preferred embodiment of the present invention, the inner peripheral wall of the blood flow path is provided with a plurality of microspheres, and the microspheres have hollow micropores; the average grain diameter of the microspheres is 5 μm, and the laying thickness of the formed microspheres is 40 μm-50 μm; and the microspheres are fixedly connected with the extracellular matrix protein coating on the inner wall of the blood flow channel.

The hollow microspheres are used to form a narrow channel through which blood flows through the central microsphere pores. This allows the process of atherosclerotic stenotic vessel thrombosis to be simulated.

In a preferred embodiment of the present invention, the blood flow path is formed in a coil shape. In practical implementation, the length of the coil, the angle of the bending angle, the number of the bending angles and the pipe diameter of the coil can be set according to requirements.

In one embodiment, the tube inner diameter of the blood flow path and the sample path may be set to 0.5-2 mm.

The utility model also provides a platelet function test kit which comprises the platelet function test device. Including but not limited to Adenosine Diphosphate (ADP) and Epinephrine (EPI) combination test cartridges and Arachidonic Acid (AA) and ADP combination test cartridges. For example, AA and ADP platelet function test kits are constituted by coating AA on the inner wall of a stirring chamber, coating ADP and PGE1 on the inner wall of another stirring chamber, and coating fibrinogen on the blood flow path.

In a preferred embodiment of the present invention, the platelet function test comprises at least one of the following tests:

blood coagulation tests, platelet aggregation tests, bleeding risk assessment tests, antiplatelet response tests, shear-mediated platelet aggregation tests, systemic hemostasis and fibrinolysis tests, hemophilia detection, and anti-thrombotic drug therapy response assessment.

In one embodiment, the bleeding risk assessment test may be a C/EPI platelet function test kit selected from a test kit in which a collagen (collagen) coating is disposed on the inner wall of the blood flow path and an Epinephrine (EPI) coating is disposed in the stirring chamber.

In one embodiment, the hemophilia (vWD) test described above may be selected from a C/ADP platelet function test kit, i.e., a test kit in which a collagen (collagen) coating is disposed on the inner wall of the blood flow path and an Adenosine Diphosphate (ADP) coating is disposed in an agitation chamber.

In one embodiment, the antithrombotic drug therapy response assessment may be performed by selecting an ASPIRIN (ASPIRIN) platelet function test kit, i.e., a test kit in which a Fibrinogen (Fibrinogen) coating is applied to the inner wall of the blood flow path and an Arachidonic Acid (AA) coating is disposed in the stirring chamber.

In one embodiment, the P2Y12 inhibitor response assessment described above may be performed using a P2Y12 platelet function test kit, i.e., a test kit in which a Fibrinogen (Fibrinogen) coating is disposed on the inner wall of the blood flow path and an ADP coating and a PGE1 coating are applied in a stirred chamber.

The utility model also provides an application of the platelet function testing device or the platelet function testing kit in drug screening. The above medicine is an antiplatelet medicine. The antiplatelet agent is selected from the group consisting of a thromboxane A2 inhibitor, an ADP receptor antagonist/P2Y 12 receptor antagonist, a thrombin receptor antagonist, a 5-hydroxytryptamine (5-HT) receptor antagonist, a platelet Glycoprotein (GP) IIb/IIIa receptor inhibitor, and a phosphodiesterase inhibitor.

The term in the present invention is to be interpreted:

AA: arachidonic acid;

ADP: adenosine diphosphate;

ECM is extracellular matrix;

EPI: adrenalin;

a Migration distance of Migration of Migration distance;

PRP: platelet rich plasma;

PPP: platelet-depleted plasma;

RBC, red blood cell;

vWD is hemophilia;

TEG thrombelastogram.

Compared with the prior art, the utility model has the beneficial effects that:

compared with the prior art, the platelet function testing device provided by the utility model has no complex sampling system and motion control system, and eliminates the potential cross contamination risk and testing uncertainty of sampling. And the testing device can completely simulate the environment in the blood vessel, and improves the accuracy, consistency and reliability of the test. In addition, the platelet function testing device is simple in design, greatly reduces the purchase and maintenance cost of the testing system, and has good maintainability. The platelet function testing device provided by the utility model can be used for testing the platelet function without waiting for blood coagulation and directly loading the sample, and has the advantage of short testing time.

The present invention also provides a test kit comprising the above platelet function test device, which can be used for blood coagulation test, platelet aggregation test, bleeding risk assessment test, antiplatelet reaction test, shear-mediated platelet aggregation test, systemic hemostasis and fibrinolysis test, hemophilia detection and antithrombotic drug treatment reaction assessment. The platelet function testing device or the platelet function testing kit can be used for drug screening.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.

FIG. 1 is a flow chart of a conventional biochemical test for platelet aggregation;

fig. 2 is a test schematic diagram of the test apparatus provided in embodiment 1 of the present invention;

FIG. 3 is a schematic diagram of the structure of ADP and EPI test cartridges;

FIG. 4 is a schematic diagram of AA and ADP test cartridges;

FIG. 5 is a schematic diagram of the thrombus formation of a blood vessel simulating stenosis.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. The components of embodiments of the present invention generally described and illustrated in the figures herein may be arranged and designed in a wide variety of different configurations.

Thus, the following detailed description of the embodiments of the present invention, presented in the figures, is not intended to limit the scope of the utility model, as claimed, but is merely representative of selected embodiments of the utility model. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

It should be noted that: like reference numbers and letters refer to like items in the following figures, and thus, once an item is defined in one figure, it need not be further defined and explained in subsequent figures.

In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", "clockwise", "counterclockwise", etc. indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings or orientations or positional relationships that the products of the present invention are usually placed in when used, and are only used for convenience of describing the present invention and simplifying the description, but do not indicate or imply that the device or element to which the description refers must have a specific orientation, be constructed in a specific orientation, and be operated, and thus, should not be construed as limiting the present invention. Furthermore, the terms "first," "second," "third," and the like are used solely to distinguish one from another and are not to be construed as indicating or implying relative importance.

Furthermore, the terms "horizontal", "vertical", "overhang" and the like do not imply that the components are required to be absolutely horizontal or overhang, but may be slightly inclined. For example, "horizontal" merely means that the direction is more horizontal than "vertical" and does not mean that the structure must be perfectly horizontal, but may be slightly inclined.

In the description of the present invention, it should also be noted that, unless otherwise explicitly specified or limited, the terms "disposed," "mounted," "connected," and "connected" are to be construed broadly and may, for example, be fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood in a specific case to those of ordinary skill in the art.

Example 1

Referring to fig. 2 and 3, the present embodiment provides a platelet function testing device, which includes a bottom plate (see fig. 3), on which a sample chamber, a sample passage, an agitation chamber, and a blood flow passage are pre-formed, wherein the sample chamber is communicated with the agitation chamber through the sample passage, and the agitation chamber is communicated with the blood flow passage.

The sample to be tested is loaded from the sample chamber, and under the thrust action of the stirring chamber, the sample to be tested flows into the stirring chamber along the sample passage and finally flows into the blood flow passage. In the embodiment, the magnetic stirring rod is arranged in the stirring chamber, and the motor arranged below the stirring rod drives the impellers with opposite magnetic poles to rotate, so that stirring is realized, and power is provided for blood flow.

The stirring chamber has a coating of platelet-inducer on its inner wall, and blood flowing through the stirring chamber can rapidly dissolve platelet-inducer in the blood in the stirring chamber and the sample chamber under the action of stirring, thereby simulating platelet activation. The coating is applied to the tubing by dropping it onto the micro tubing with a controlled dosing device and allowing it to dry naturally.

The blood flowing into the blood flow channel has an extracellular matrix protein coating on the inner wall of the blood flow channel, so that platelets are attached and aggregated to cause hemostasis obstruction, and the whole process of forming the hemostasis obstruction by platelet aggregation is simulated. The platelet performance can be judged from the distance the blood has traveled.

Figure 3 provides an ADP and EPI platelet function test kit. The kit also comprises a matched use instruction, a bottom plate and a packing box. The bottom plate is provided with 3 grooves which are respectively used as a sample chamber and two stirring chambers, and a sample passage is led out from the sample chamber and is divided into two branches. One branch was used for ADP testing and the other branch was used for Epinephrine (EPI) testing. The inner walls of the two stirring chambers are coated with an ADP coating and an EPI coating, respectively. A collagen (collagen) coating is provided on the inner wall of the blood flow passageway.

Studies have shown that most patients with extended migration distances for collagen/ADP testing exhibit abnormalities in primary hemostasis, which may expose them to risk during surgery. Therefore, the kit provided by the utility model can be used for preoperative hemorrhage risk management evaluation.

When the blood test box is used, an operator only needs to use the pipettor to take about 200 microliters of whole blood and add the whole blood into the test box, and the test can be completed within about 4 minutes, so that the blood test box has the advantages of simplicity and convenience in operation, and has good implementation real-time performance.

Example 2

Referring to fig. 4, the present embodiment provides a kit for testing platelet function of AA and ADP.

The kit also comprises a matched use instruction, a bottom plate and a packing box. The bottom plate is provided with 3 grooves which are respectively used as a sample chamber and two stirring chambers, and a sample passage is led out from the sample chamber and is divided into two branches. One branch was used for aspirin treatment response assessment and the other branch was used for P2Y12 inhibitor response assessment.

The inner walls of the chambers of the branches used for aspirin treatment response assessment were coated with Arachidonic Acid (AA), and the inner walls of the other branch chambers were coated with ADP coating and alprostadil (PGE1) coating. A Fibrinogen (Fibrinogen) coating is provided on the inner wall of the blood flow passageway.

Studies have shown that the migration distance is extended for most patients taking aspirin. The prolongation of the migration distance of aspirin patients is closely related to aspirin resistance. The platelet reactivity test can accurately reflect the drug resistance reaction of patients to aspirin. The P2Y12 assay assesses P2Y12 inhibitor response by measuring ADP-induced platelet adhesion and aggregation to detect platelet P2Y12 receptor blockade in patients receiving P2Y12 antagonist therapy.

Example 3

Referring to FIG. 5, the structure of FIG. 5 is shown simulating the formation of a thrombus in an atherosclerotic stenosed vessel. This example provides a platelet function test kit. The difference from example 1 is only that microspheres having a thickness of about 45 μm are provided in the blood flow path, the microspheres have an average particle diameter of 5 μm, the microspheres have hollow micropores, a narrow channel having a diameter of about 0.5 mm is formed by using the hollow microspheres, and blood flows through the micropores of the microspheres in the middle. This allows the process of atherosclerotic stenotic vessel thrombosis to be simulated. The kit can be used for preventing accidents and the reaction of patients to drugs.

Example 4

The only difference compared to example 1 is that the platelet-inducer is different and that both stirring chambers are coated with an ADP coating on their inner walls. A collagen (collagen) coating is provided on the inner wall of the blood flow passageway.

Example 5

The only difference compared to example 1 is that the platelet-inducer is different, being coated with dipyridamole and cilostazol coatings on the inner walls of the two mixing chambers, respectively. A coating of thromboplastin is disposed on the inner wall of the blood flow passageway.

The above is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and various modifications and changes will occur to those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (9)

1. A platelet function testing device is characterized by comprising a bottom plate, wherein a sample chamber, a sample passage, an agitating chamber and a blood flow passage are prefabricated on the bottom plate, the sample chamber is communicated with the agitating chamber through the sample passage, and the agitating chamber is communicated with the blood flow passage; a platelet-inducer coating, platelet-inducer microbeads or microparticles on the interior wall of the stirring chamber, the interior wall of the blood flow passageway having a coating of extracellular matrix proteins.

2. The platelet function test device according to claim 1, wherein the platelet inducer is selected from a platelet aggregation promoter and/or a platelet aggregation inhibitor;

the platelet aggregation promoter is selected from any one of the following substances:

ADP, epinephrine, and thromboxane a 2;

the platelet aggregation inhibitor is selected from antiplatelet drugs.

3. A platelet function testing device according to claim 2, wherein said antiplatelet agent is selected from the group consisting of a thromboxane a2 inhibitor, an ADP-P2Y12 receptor antagonist, a thrombin receptor antagonist, a 5-hydroxytryptamine receptor antagonist, a platelet glycoprotein iib/iiia receptor inhibitor, and a phosphodiesterase inhibitor.

4. A platelet function testing device according to claim 3, wherein said thromboxane a2 inhibitor is selected from the group consisting of: aspirin, arachidonic acid, or PGE 1.

5. A platelet function testing device according to claim 1, wherein the number of the stirring chambers is the same as the number of the blood flow paths; when the number of the stirring chambers is two, the sample passage is led out from one of the sample chambers to be divided into two branch sample passages, the two branch sample passages are respectively communicated with the two stirring chambers, and the two blood flow passages are respectively communicated with the two stirring chambers.

6. A platelet function testing device according to claim 5, wherein the inner peripheral wall of said blood flow path is provided with a plurality of microspheres having hollow micropores; the average grain diameter of the microspheres is 5 μm, and the laying thickness of the microspheres is 40 μm-50 μm; and a plurality of the microspheres are fixedly connected with the extracellular matrix protein coating on the inner wall of the blood flow channel; the tube inner diameters of the blood flow path and the sample path are 0.5-2 mm.

7. A platelet function test device according to claim 1, wherein the blood flow path has a coil shape.

8. A platelet function test kit comprising the platelet function test device according to any one of claims 1 to 7.

9. A platelet function test kit according to claim 8 wherein the platelet function test includes testing of at least one of:

blood coagulation tests, platelet aggregation tests, bleeding risk assessment tests, antiplatelet response tests, shear-mediated platelet aggregation tests, systemic hemostasis and fibrinolysis tests, hemophilia detection, and anti-thrombotic drug therapy response assessment.

Images